TRAIL Antibody [SB91a] | 99-762

TRAIL Antibody [SB91a] | 99-762 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant TRAIL

Research Area: Cancer, Immunology

Tested Application: WB, IHC-Fr, Flow, Blocking, IP, Adhesion

Application: TRAIL Antibody [SB91a] for use in ELISA assays.

Specificiy: TRAIL

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: [SB91a]

Isotype: IgG2b

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in borate buffered saline, pH 8.2; No preservatives or amine-containing buffer salts added

Concentration: 0.5 mg/mL

Storage Condition: Store vial at 2-8˚C

Alternate Name: CD253, Apo-2 ligand, Apo-2L, TNFSF10

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines. This type II transmembrane protein is expressed by several cytotoxic immune cells, including natural killer cells and activated T cells, and is selective for tumorigenic and virally infected cells. TRAIL can bind to DR4 and DR5 receptors on target cells which facilitates recruitment of numerous signaling proteins to form a death-inducing signaling complex. This signaling complex is then believed to propagate the apoptotic signal through the recruitment and activation of caspase-8. Numerous studies have identified TRAIL as a potent apoptotic factor in a variety of human cancer cell lines, but this cytokine does not appear to affect normal cell lines. Therefore, the selectivity and anti-tumorigenic properties of TRAIL make it an intriguing and potentially therapeutic agent in the treatment of cancer.